The Life Sciences Report
Notable Quotes
"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More >
"ATHX is an exciting story and definitely a company to watch." (6/6/13) Athersys Inc. - The Life Sciences Report Interview with Christian Glennie More >
"NEO has been able to continue to grow the topline nicely and maintain margins of more than 45%." (5/30/13) NeoGenomics Laboratories - The Life Science Report with Kevin DeGeeter More >
"OPK's 4Kscore is approved in Europe and should be approved in the U.S. sometime in 2013." (5/30/13) OPKO Health Inc. - The Life Science Report with Kevin DeGeeter More >
"CTH is very early in the game with a very good and relatively derisked idea." (5/30/13) Cynapsus Therapeutics Inc. - The Life Science Report with Ori Hershkovitz More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk High: | ||
Experts Commenting on This Company
|
Verisante Technology Inc.TICKER: VRS:TSX.VVerisante Technology Inc. is committed to helping save lives through the commercialization of innovative systems for the detection of cancer. The company's initial focus is skin cancer, including basal cell carcinoma, squamous cell carcinoma and melanoma. Verisante has licensed a technology developed by the BC Cancer Agency for in vivo, real-time, noninvasive skin measurements. This platform technology may also be applied to detection systems for other types of cancer including lung, gastrointestinal, colorectal and cervical cancers. |
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Comments:
Brian Marckx, Zacks Small-Cap Research (5/31/13) "Verisante Technology Inc.'s Aura officially launched in Canada and Europe. Initial sales commenced in Q1/13. We expect more substantial revenue towards the back half of the year as the roll-out will likely be measured and drawn out. . .we view the recent progress with establishing greater distribution as a meaningfully positive operational development and the recent string of various award wins and recognitions as important votes of confidence in the technology and product from the medical and scientific communities. . .we are maintaining our $2.25/share price target and Outperform rating." -Zacks Small-Cap Research
The Life Sciences Report Interview with Jim Letourneau (1/17/13) "Verisante Technology Inc. has a technology that uses Raman spectroscopy to get compositional data that indicates whether a mole is cancerous or not. Other technologies use pattern recognitions from millions of images of moles. Such methods don't utilize compositional data and, consequently, don't work very well. While Verisante has a long road to commercialization, I think dermatologists will be open to using this tool because it's a fast and efficient way to screen. The exciting part is that Verisante's technology doesn't just work on skin cancer. Strong data from a 2011 pilot study and a 2012 follow-up have led to the company working on applications for regulatory approval. Overall, Verisante's platform is very compelling. The technology behind the Verisante Core for lung cancer detection was also named a top 10 cancer breakthrough of 2011 by the Canadian Cancer Society." More >
Brian Marckx, Zacks Small-Cap Research (12/3/12) "Verisante Technology Inc. management continues to hit milestones and at the same time is driving awareness of Aura. . . Aura continues to be recognized as one of the leading novel medical technologies throughout the world . . .Aura has gained significant recognition and racked up an impressive number of awards related to novel, high-potential medical device technologies over the past 18 months. . .we continue to model an assumed U.S. launch in mid to late 2015." -Zacks Small-Cap Research
